S

SynAct Pharma AB
STO:SYNACT

Watchlist Manager
SynAct Pharma AB
STO:SYNACT
Watchlist
Price: 20.55 SEK -0.48% Market Closed
Market Cap: 1.1B SEK

Relative Value

There is not enough data to reliably calculate the relative value of SYNACT.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SYNACT Relative Value
Base Case
Not Available
S
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
-10
Median 5Y
-16.6
Industry
23.7
Forward
-9.1
vs History
vs Industry
Median 3Y
-9.2
Median 5Y
-17.5
Industry
22
vs History
vs Industry
Median 3Y
-9
Median 5Y
-17.4
Industry
23.8
vs History
52
vs Industry
29
Median 3Y
4.6
Median 5Y
6.6
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
Median 3Y
-8.1
Median 5Y
-15.1
Industry
6.4
Forward
-8.5
vs History
vs Industry
Median 3Y
-8.1
Median 5Y
-15.1
Industry
7
Forward
-8.5
vs History
vs Industry
Median 3Y
-8.8
Median 5Y
-16.9
Industry
8.3
vs History
vs Industry
Median 3Y
-8.8
Median 5Y
-16.9
Industry
6.5
vs History
52
vs Industry
37
Median 3Y
4.8
Median 5Y
7.3
Industry
5.7

Multiples Across Competitors

SYNACT Competitors Multiples
SynAct Pharma AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
SynAct Pharma AB
STO:SYNACT
1.1B SEK 0 -10.3 -8.9 -8.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 738 486.8 -160 354 -194 720.9 -192 498.9
US
Abbvie Inc
NYSE:ABBV
401.5B USD 6.7 171 16.5 23.5
US
Amgen Inc
NASDAQ:AMGN
173.9B USD 4.8 24.8 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
149.8B USD 5.2 18.5 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.5B USD 9.8 31.2 22.8 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 088.1 -532.8 -580.2 -564.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD 5.6 17.4 16.6 18.8
AU
CSL Ltd
ASX:CSL
86.8B AUD 3.7 19.2 12.9 16.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.9B USD 16.2 1 192 156.5 189.8
NL
argenx SE
XBRU:ARGX
44.1B EUR 14.4 33.9 58.4 60
P/S Multiple
Revenue Growth P/S to Growth
SE
S
SynAct Pharma AB
STO:SYNACT
Average P/S: 3 374 064.1
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 738 486.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 088.1
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.2
46%
0.4
NL
argenx SE
XBRU:ARGX
14.4
49%
0.3
P/E Multiple
Earnings Growth PEG
SE
S
SynAct Pharma AB
STO:SYNACT
Average P/E: 188.5
Negative Multiple: -10.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 354 N/A N/A
US
Abbvie Inc
NYSE:ABBV
171
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
9%
1.9
AU
CSL Ltd
ASX:CSL
19.2
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 192
N/A N/A
NL
argenx SE
XBRU:ARGX
33.9
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
S
SynAct Pharma AB
STO:SYNACT
Average EV/EBITDA: 39.3
Negative Multiple: -8.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 720.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
11%
1.5
AU
CSL Ltd
ASX:CSL
12.9
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
156.5
N/A N/A
NL
argenx SE
XBRU:ARGX
58.4
839%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
S
SynAct Pharma AB
STO:SYNACT
Average EV/EBIT: 45.3
Negative Multiple: -8.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 498.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
13%
1.4
AU
CSL Ltd
ASX:CSL
16.1
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
189.8
N/A N/A
NL
argenx SE
XBRU:ARGX
60
N/A N/A